Monday, September 27, 2021 1:50:55 PM
Blaks-Ops ..You are right ,
Even talking about our second patient , first treated by EIND or compassionate ,
M-i-L...
She was injected first with leronlimab Nov 25 2019 as a monotherapy ,
She presented at the time with metastatic breast cancer , with many lesions in the liver , lungs and 18 in her brain.
At this time she was given 2-3 months by her doctors.
This was November 25,2019 , today September 27, 2021 , being only on leronlimab , few weeks ago Dr NP said , liver , lungs no big problems , and in a brain just one small lesion left..
And we heard testimonials of some others .
Will everyone be save , I am sure not , but maybe with time in some combination we will be close to it.
I will be interested to see results with check point inhibitor , we probably don't need it as much since leronlimab also affecting same endpoints , but maybe together results will be even better..
GLTU.
Even talking about our second patient , first treated by EIND or compassionate ,
M-i-L...
She was injected first with leronlimab Nov 25 2019 as a monotherapy ,
She presented at the time with metastatic breast cancer , with many lesions in the liver , lungs and 18 in her brain.
At this time she was given 2-3 months by her doctors.
This was November 25,2019 , today September 27, 2021 , being only on leronlimab , few weeks ago Dr NP said , liver , lungs no big problems , and in a brain just one small lesion left..
And we heard testimonials of some others .
Will everyone be save , I am sure not , but maybe with time in some combination we will be close to it.
I will be interested to see results with check point inhibitor , we probably don't need it as much since leronlimab also affecting same endpoints , but maybe together results will be even better..
GLTU.
Recent CYDY News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/02/2025 10:15:21 PM
